ZFIN ID: ZDB-FISH-150901-15502
Fish name: WT + MO1-rx3 + MO3-rx3
Genotype: WT
Targeting Reagent: MO1-rx3, MO3-rx3
HUMAN DISEASE MODELED by WT + MO1-rx3 + MO3-rx3
No data available
GENE EXPRESSION
Gene expression in WT + MO1-rx3 + MO3-rx3
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab4-h3 chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
Ab4-h3 standard conditions Fig. 6 with imageFig. 7 with image from Muthu et al., 2016
Reporter gene expression No data available
PHENOTYPE
Phenotype in WT + MO1-rx3 + MO3-rx3
Phenotype Conditions Figures
eye aplastic, abnormal standard conditions Fig. 6 with image from Tessmar-Raible et al., 2007
hypothalamus nr5a1a expression absent, abnormal control Fig. 7 with image from Muthu et al., 2016
hypothalamus pomca expression absent, abnormal control Fig. 7 with image from Muthu et al., 2016
hypothalamus pomca expression amount, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus ab4-h3 labeling amount, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus nr5a1a expression amount, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus shha expression decreased amount, abnormal standard conditions Fig. 6 with image from Muthu et al., 2016
hypothalamus etv4 expression increased amount, abnormal standard conditions Fig. 5 with image from Muthu et al., 2016
hypothalamus ab4-h3 labeling increased amount, abnormal standard conditions Fig. 6 with imageFig. 7 with image from Muthu et al., 2016
hypothalamus ptch2 expression spatial pattern, abnormal control Fig. 7 with image from Muthu et al., 2016
hypothalamus nkx2.1 expression spatial pattern, abnormal control Fig. 7 with image from Muthu et al., 2016
hypothalamus rx3 expression spatial pattern, abnormal control Fig. 7 with image from Muthu et al., 2016
hypothalamus rx3 expression spatial pattern, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus nkx2.1 expression spatial pattern, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus ptch2 expression spatial pattern, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016
hypothalamus mitotic cell cycle process increased occurrence, abnormal standard conditions Fig. 6 with imageFig. 7 with image from Muthu et al., 2016
hypothalamus mitotic cell cycle process occurrence, ameliorated chemical treatment: SMO receptor agonist Fig. 7 with image from Muthu et al., 2016

CITATIONS  (3)